Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma

Urothelial carcinoma (UC), including bladder UC (90% –95%) and upper urinary tract UC (5%–10%), are estimated to account for 85,000 new cancer cases and 18,000 deaths in the United States in 2018, making UC the fourth and twelfth most common cancer in men and women, respectively [1]. Patients with advanced UC (aUC) generally show poor prognosis wi th median overall survival (OS) of 3 to 6 months without treatment and 13 to 16 months with systemic chemotherapy [2]. The first prognostic model predicting survival of patients with aUC was developed by Bajorin et al., which consisted of Karnofsky performance status (KPS) and the presence of viscer al metastasis as dual independent predictors of OS [3].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research